SGMO
SGMO
NASDAQ · Biotechnology

Sangamo Therapeutics Inc

$0.26
+0.01 (+5.35%)
As of Apr 1, 10:08 PM ET ·
Financial Highlights (FY 2026)
Revenue
114.23M
Net Income
-193,538,968
Gross Margin
Profit Margin
-169.5%
Rev Growth
-19.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 31.5% 31.5%
Operating Margin -179.9% -161.9% -14.2% -12.4%
Profit Margin -169.5% -161.0% -12.9% -14.6%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 114.23M 141.86M 23.70M 20.49M
Gross Profit 7.47M 6.46M
Operating Income -205,470,182 -229,661,157 -3,376,071 -2,532,481
Net Income -193,538,968 -216,325,225 -3,056,252 -2,992,966
Gross Margin 31.5% 31.5%
Operating Margin -179.9% -161.9% -14.2% -12.4%
Profit Margin -169.5% -161.0% -12.9% -14.6%
Rev Growth -19.5% -19.5% +16.7% +8.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 61.71M 62.11M
Total Equity 96.81M 91.91M
D/E Ratio 0.64 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -195,332,472 -230,459,324 -4,785,189 -3,856,552
Free Cash Flow -2,136,953 -2,270,748